

What we claim is:

1. A composition of matter comprising, as active agents,
an adjuvant-effective amount of at least one sialidase
and (2) an unrelated antigenic vaccine which gives rise
to antibodies against an organism whose portal of
entry, site of reproduction or site of disease
causation is the mucosa, in a pharmaceutically
acceptable carrier.
2. A composition of claim 1 wherein the carrier is a solid
support.
3. A composition of claim 1 which is a liquid.
4. A composition of claim 1 which is a powder.
5. A composition of claim 1 which is in capsule or tablet
form.
6. A composition of claim 1 containing, additionally,
anti-CD43 antibodies.
7. A composition of claim 1 which is a gel, a cream or a
suppository.
8. A method of enhancing immune response in mammal by
administration to the mucosa of an immune enhancing
effective amount of sialidases in a pharmaceutically
accepted carrier in conjunction with a antigenic
vaccine.
9. A method of claim 8 wherein sialidase is administered
in the form of drops or a spray.
10. A method of claim 8 wherein sialidase is administered
in powder form.

11. A method of claim 8 wherein sialidase is administered on a solid support.

12. A method of claim 8 wherein sialidase is administered orally.

13. A method of claim 8 wherein sialidase is administered in animal feed.

14. A method of claim 8 wherein sialidase is administered in conjunction with an anti-CD4 antibody.

15. A method of claim 14 wherein the anti-CD4 antibody is an anti-CD43 antibody.